All In Biotech

Drug Trial Radar · NCT06904261

A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Treatment With Migalastat in Pediatric Subjects (Aged 2 to < 12 Years) With Fabry Disease and Amenable GLA Variants

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

8

Planned (sponsor's estimate)

Start

Jan 8, 2026

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of migalastat treatment in pediatric subjects 2 to \< 12 years of age with Fabry disease and with amenable GLA variants.

Conditions

  • Fabry Disease

Interventions

  • Migalastat HCl 20 mgDrug

    Migalastat will be supplied as 20-mg dispersible tablets. Migalastat 20-mg dispersible tablets contain 16 mg migalastat free base.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Incidence of TEAEs, SAEs, and AEs leading to discontinuation of study drugTime frame: Day 1 (after dosing) through Month 12 and follow-up (30 days after last dose)
  2. Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of MigalastatTime frame: 0 to 12 hours postdose during the first month of study and trough samples at Months 6 and 12
  3. Pharmacokinetics (PK): Minimum Observed Plasma Concentration (Cmin) of MigalastatTime frame: 0 to 12 hours postdose during the first month of study and trough samples at Months 6 and 12
  4. Pharmacokinetics (PK): Area Under The Plasma Concentration-time Curve Over The Dosing Interval (AUCtau) of MigalastatTime frame: 0 to 12 hours postdose during the first month of study and trough samples at Months 6 and 12

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • Emory Genetics

    Atlanta, Georgia · Recruiting

  • University of Minnesota Masonic Children's Hospital

    Minneapolis, Minnesota · Recruiting

  • Atrium Health Levine Children's Hospital

    Charlotte, North Carolina · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • Lysosomal and Rare Disorders Research and Treatment Center, Inc.

    Fairfax, Virginia · Recruiting

  • Universitair Ziekenhuis (UZ) Leuven

    Leuven, Vlaams-Brabant, Belgium · Recruiting

  • Universitäetsklinikum Müenster (UKM) Klinik für Kinder- und Jugendmedizin - Allgemeine Paediatrie

    Münster, North Rhine-Westphalia, Germany · Recruiting

  • Kitasato University Hospital

    Sagamihara, Kanagawa, Japan · Recruiting

  • Hospital Universitario de la Paz

    Madrid, Madrid, Spain · Recruiting

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, United Kingdom · Not yet recruiting

  • Manchester University NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.